How does rofecoxib's selectivity inhibit cox 2 not cox 1?

Rofecoxib is a COX-2–selective nonsteroidal anti-inflammatory drug (NSAID). Its selectivity comes from how well its bulky structure fits into the COX-2 enzyme compared with COX-1.

- Structural difference: COX-2 has a larger, more flexible pocket next to the main catalytic site (a so‑called side pocket) because of specific amino acid substitutions that are not present in COX-1. This pocket is not as available in COX-1.

- How rofecoxib fits: Rofecoxib has a bulky aryl group with a sulfonyl-containing moiety. This bulky group can extend into and occupy the COX-2 side pocket and form favorable interactions with residues in that pocket, effectively blocking the enzyme's active site and inhibiting COX-2 activity.

- Why it doesn’t fit COX-1 well: In COX-1, the corresponding space is smaller or sterically hindered, so rofecoxib cannot bind as well or at all. The result is much weaker (or negligible) inhibition of COX-1.

- Net effect: Rofecoxib strongly inhibits COX-2–driven prostaglandin production while sparing COX-1 activity to a larger extent, which is why it’s described as COX-2 selective.

Note: The selectivity is not absolute—at higher doses some COX-1 inhibition can occur—but the drug is designed to favor COX-2 binding due to the structural differences in the enzymes. If you’d like, I can summarize the key residues involved or provide a simple schematic.